Psilocybin for OCD: Systemic Barriers to Integrating Psychedelic Therapies into Mental Health Care
Original framing: “What Happens When You Try to Treat OCD With Psilocybin” — Wired
Psychedelics were mainstream psychiatric treatments in the 1950s–60s before being criminalized under Nixon’s administration, which prioritized pharmaceutical profits and social control over therapeutic innovation. The FDA’s recent 'breakthrough therapy' designation for psilocybin in OCD reflects a cyclical pattern of medicalization and de-medicalization tied to corporate and political interests. OCD itself was only formally recognized in the 20th century, with earlier eras pathologizing obsessive thoughts as moral failings or demonic possession.
The psilocybin-for-OCD narrative exemplifies how Western medicine extracts and commodifies Indigenous and Afro-diasporic healing traditions while ignoring their cultural contexts and systemic roots.
The cyclical suppression of psychedelics—from Nixon’s War on Drugs to today’s venture-capital-funded 'psychedelic renaissance'—reveals a pattern of medicalization serving corporate and state interests over patient needs. Indigenous frameworks, which treat doubt as a sacred dialogue rather than a disorder, offer a corrective to the individualistic, pharmaceutical-driven approach dominating headlines. Meanwhile, marginalized communities, who have long used psychedelics informally, remain excluded from both research and policy. A systemic solution requires decriminalization, decolonized research, and structural reforms in mental healthcare—centering community care over profit-driven 'breakthroughs.' The trickster’s laughter reminds us that no substance can 'treat' a society that has pathologized the human condition itself.